250 related articles for article (PubMed ID: 37796513)
1. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.
Qin S; Kudo M; Meyer T; Bai Y; Guo Y; Meng Z; Satoh T; Marino D; Assenat E; Li S; Chen Y; Boisserie F; Abdrashitov R; Finn RS; Vogel A; Zhu AX
JAMA Oncol; 2023 Dec; 9(12):1651-1659. PubMed ID: 37796513
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
3. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
7. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
[TBL] [Abstract][Full Text] [Related]
11. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
14. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
18. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S; Bi F; Gu S; Bai Y; Chen Z; Wang Z; Ying J; Lu Y; Meng Z; Pan H; Yang P; Zhang H; Chen X; Xu A; Cui C; Zhu B; Wu J; Xin X; Wang J; Shan J; Chen J; Zheng Z; Xu L; Wen X; You Z; Ren Z; Liu X; Qiu M; Wu L; Chen F
J Clin Oncol; 2021 Sep; 39(27):3002-3011. PubMed ID: 34185551
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
